Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
6
50%
Ph phase_1
5
42%
Ph phase_3
1
8%

Phase Distribution

5

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
6(50.0%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(3)
Other(8)

Detailed Status

unknown8
Completed3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (41.7%)
Phase 26 (50.0%)
Phase 31 (8.3%)

Trials by Status

unknown867%
completed325%
not_yet_recruiting18%

Recent Activity

0 active trials
Showing 5 of 12
unknownphase_1

Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers

NCT05622825
unknownphase_3

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

NCT04292769
completedphase_1

Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

NCT02425748
completedphase_1

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

NCT01783951
completedphase_1

Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

NCT02418481
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05622825Phase 1

Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers

Unknown
NCT04292769Phase 3

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

Unknown
NCT02425748Phase 1

Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

Completed
NCT01783951Phase 1

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

Completed
NCT02418481Phase 1

Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

Completed
NCT02644863Phase 2

Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer

Unknown
NCT02487017Phase 2

DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma

Unknown
NCT02202928Phase 2

Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer

Unknown
NCT02487550Phase 2

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

Not Yet Recruiting
NCT02415699Phase 2

DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer

Unknown
NCT01821495Phase 2

Study of DC-CIK to Treat NPC

Unknown
NCT00862303Phase 1

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

Unknown

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12